Brief: Syndax Announces Publication In The Journal Of Clinical Oncology Of Data From The Pivotal Augment-101 Trial Of Revumenib
12/08/2024 12:50
Aug 12 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX ANNOUNCES PUBLICATION IN THE JOURNAL OF CLINICAL
ONCOLOGY
OF DATA FROM THE PIVOTAL AUGMENT-101 TRIAL OF REVUMENIB IN
RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA
* SYNDAX PHARMACEUTICALS INC -NDA FILING FOR REVUMENIB IN
R/R
KMT2AR ACUTE LEUKEMIA IS BEING REVIEWED UNDER RTOR; PDUFA ACTION
DATE OF DECEMBER 26, 2024
Source text for Eikon: ID:nPn44rztra
Further company coverage: SNDX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million